What routine examinations are required during pazopanib treatment?

During the treatment of advanced renal cell carcinoma or soft tissue sarcoma with Pazopanib, reasonable and continuous monitoring is an important guarantee to ensure efficacy and safety. As a multi-target tyrosine kinase inhibitor, pazopanib may also affect the function of multiple organs while blocking the angiogenesis signaling pathway. Therefore, a series of routine examinations are required during treatment to evaluate drug tolerance and potential toxic reactions to ensure smooth progress of treatment.

First, liver function monitoring is key in treatment. One of the most common adverse reactions of pazopanib is an increase in liver enzymes, especially ALT and AST. Therefore, it is recommended to conduct liver function tests every 2 weeks in the first 3 months of medication, and then once a month. If there is an abnormal increase in liver enzymes, the dose should be adjusted or the medication should be suspended according to the severity. Secondly, blood pressure monitoring cannot be ignored. Pazopanib has the side effect of raising blood pressure, so patients need to assess their basal blood pressure level before taking the drug, and monitor it weekly during treatment, especially in the first month, to detect and control hypertension in a timely manner to prevent cardiovascular complications.

Electrocardiogram (ECG) examination is also very necessary, especially paying attention to changes in the QT interval. Although QT prolongation is not the most common side effect of pazopanib, it may induce serious abnormal heart rhythms in some patients who are susceptible to arrhythmias. Therefore, regular electrocardiogram checks are required during the initial treatment and dose adjustment period. Furthermore, routine blood tests and kidney function tests are equally important. Long-term medication may cause a decrease in white blood cell or platelet counts, so regular hematology tests should be performed to avoid the risk of infection and bleeding.

In addition, to evaluate the effect of treatment, tumor changes should be evaluated every 8–12 weeks in conjunction with imaging examinations (such asCT, MRI). When necessary, tumor markers, weight changes, appetite status, etc. will be combined to comprehensively judge the efficacy and degree of adverse reactions. Some patients also need to pay attention to changes in thyroid function, so thyroid hormone level testing should also be included in routine monitoring items.

Reference materials:https://www.votrient.com/